Rupert Martin Bauersachs

Rupert Martin Bauersachs is a German angiologist and internist, director of the Department of Vascular Medicine - Angiology at the Darmstadt Hospital and Professor at the Goethe University Frankfurt.

Bauersachs studied medicine at the Ludwig Maximilian University of Munich and the Technical University of Munich from 1977 to 1983, at the Oxford University Medical School 1981. In 1984 he was appointed to the Dr. med. From 1984 to 1985 he was post-doc Research Fellow at the Institute of Pharmacology of the Technical University of Munich and from 1985 to 1987 Research Fellow of the American Heart Association at the Department of Physiology and Biophysics of the University of Southern California Los Angeles. He completed a specialist training as an internist at the Klinikum München-Bogenhausen from 1987 to 1993 and received his specialist training in angiology angiologist, diabetologist, phlebologist and haemostaseologist at the Universities of Frankfurt and Mainz from 1993 to 1999. In 1999, he completed his habilitation on ischemia and reperfusion disorders and obtained a postgraduate degree in angiology. In 1999, he was recognized as a Fellow of the International Union of Angiology.

Bauersachs took over the provisional head of the Department of Vascular Medicine of the Goethe University Frankfurt am Main from 1999 to 2003 and co-founded the first German university vascular center at the University of Frankfurt in 2000. He was appointed director of the Department of Angiology, Darmstadt Hospital and co-founder of the Darmstadt Vascular Center in 2003. In 2004 Bauersachs received an unscheduled professorship at the University of Frankfurt am Main and a visiting professorship Vulnerable individuals and populations - VIP at the Center for Thrombosis and Hemostasis (CTH) of the University of Mainz in 2012.

He is the scientific director of the Action Alliance Thrombosis, which he co-initiated in 2014, and which organizes the World Thrombosis Day in Germany.

• Venous thromboembolism
• Peripheral arterial disease
• New antithrombotic substances
• Antithrombotic therapy in vulnerable individuals and populations, e.g. pregnant women, tumor patients, the elderly, renal impairment
• Thrombophilia
• Heparin-induced thrombocytopenia
• Microcirculation

Bauersachs propagated outpatient treatment of deep vein thrombosis in Germany in the late 1990s and the acute treatment and prolonged secondary prevention of venous thrombosis with direct oral anticoagulants ten years later. For the neglected clinical entity of superficial venous thrombosis (thrombophlebitis), a team with Bauersachs could establish an evidence-based therapy for this common clinical picture in 2010. For vulnerable thrombosis populations, including pregnant women, the elderly, renal insufficiency or cancer, Bauersachs was able to lead or co-design new studies that produced guideline-relevant results.

Critical implementation of the research results in clinical practice is a concern to him, also with the aim to avoid over- and undertreatment, for example in thrombophilia, use of oral contraceptives, diagnosis of thrombosis including gender-specific aspects, quality of care, and patient preference, as well as in complex treatment decision on the duration of extended anticoagulation in venous thromboembolism.

As scientific director of the Action Alliance Thrombosis, he was instrumental in the development of an easy-to-use algorithm for the complex investigation of anticoagulation time in venous thromboembolism ("anticoagulation traffic light system").

• Council board member of the German Society of Angiology
• Council board member of the German Society for Phlebology

• Publications (PubMed)
• Publications (ResearchGate)